Adial pharmaceuticals announces pricing of $0.75 million at-the-market registered direct offering

Charlottesville, va., feb. 24, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase $0.75 million of its common stock in an at-the-market registered direct offering.
ADIL Ratings Summary
ADIL Quant Ranking